DeepMatter Group PLC - Bristol-based company focused on digitising chemistry - Says it has signed a trial agreement with Aurigene Pharmaceutical Services Ltd based in Hyderabad, India, to supply its DigitalGlassware platform. DeepMatter will provide its DigitalGlassware to help screen, develop and scale up chemistry procedures and to accelerate custom drug discovery and development projects.
Chief Executive Officer Mark Warne comments: "This paid for trials agreement is another positive step in our strategy to provide our DigitalGlassware platform to the major global contract research organisations where the ability to reproduce is paramount in order to accelerate the discovery of new drugs."
Current stock price: 1.21 pence
Year-to-date change: down 40%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.